Tests CAR T cell therapy in children with hard-to-treat B cell leukemia
Tests CART19 cell therapy in young patients with specific high-risk B cell acute lymphoblastic leukemia.
Key facts
- Who runs it
- Stephan Grupp MD PhD
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Orphan Indications for CD19 Redirected Autologous T Cells
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 133 people, planned
- Started
- 12 Mar 2020
- Expected to end
- 10 Mar 2037
- Type of study
- Interventional, 4 groups
- Treatments tested
- Murine CART19
- Record updated
- 6 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults up to 29 years old with CD19-positive B-cell acute lymphoblastic leukemia in one of four groups. It tests CAR T cells made from the patient's own blood.
- Age
- 0 to 29 years
- Sex
- Male and female patients can join.
- Disease stage
- CD19-positive B-ALL with documented CD19 on the cancer cells. Cohort A: hypodiploid (fewer than 45 chromosomes). Cohort B: t(17;19) translocation. Cohort C: infants with newly diagnosed very high risk KMT2A-rearranged B-ALL. Cohort D: first or later central nervous system (CNS) relapse, before cranial radiation or stem cell transplant for this relapse.
- Earlier treatment
- For CNS relapse (Cohort D), no cranial radiation (XRT) or bone marrow transplant for the current relapse. For Cohorts A and B, response to earlier treatment does not matter.
- Biomarker or test result
- CD19 on the leukemia cells in bone marrow, blood, spinal fluid or tumor tissue. Cohort A: hypodiploid karyotype. Cohort B: t(17;19) translocation. Cohort C: KMT2A rearrangement.
Main reasons for not taking part
- Active hepatitis B or active hepatitis C
- HIV infection
- Active graft-versus-host disease needing treatment with medicines affecting the whole body
- Pregnant or nursing women
- Uncontrolled active infection
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Signed informed consent form must be obtained prior to any study procedure
- Male and female patients with documented CD19+ B-ALL; a.Cohort A \& B: Patients, regardless their response to initial or relapsed B ALL therapy, with the following characteristics: i.Cohort A: Subjects with confirmation of a hypodiploid karyotype (chromosome number fewer than 45) ii.Cohort B: Subjects with cytogenetic confirmation of the chromosomal translocation t(17;19) (Cohort B) b.Cohort C: Infants w/ newly diagnosed KMT2A rearranged B-ALL classified as very high risk by the following criteria: i.Age < 3 months at diagnosis ii.Age < 6 months and WBC > 300,000x109/L at diagnosis or a poor prednisone response in induction iii.MRD positive > 0.01 (or PCR > 104) after 2 courses of standard infant ALL therapy; c.Cohort D: Subjects in a first or greater CNS relapse, prior to therapy with cranial XRT or HSCT for the current relapse
- Documentation of CD19 tumor expression in bone marrow, peripheral blood, CSF, or tumor tissue
- Age 0 to 29 years
- Adequate organ function defined as:; A serum creatinine based on age/gender as follows:; Maximum Serum Creatinine (mg/dL) Age Male Female 0 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4; ≥ 16 years 1.7 1.4; Adequate liver function:; i.ALT≤ 5 x ULN; ALT ii.Total bilirubin ≤ 3 x ULN iii.ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to ALL infiltration of the liver; c.Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and < Grade 3 hypoxia; DLCO ≥ 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the physician-investigator; d.Left Ventricular Shortening Fraction (LVSF) ≥ 28%, or Left Ventricular Ejection Fraction (LVEF) ≥ 45% by echocardiogram. In cases where quanitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualititatively normal ventricular function wll suffice
- Adequate performance status defined as Lansky or Karnofsky score ≥ 50
- Subjects of reproductive potential must agree to use acceptable birth control methods
Who cannot take part
- For subjects with a CNS relapse, prior cranial XRT or BMT for the current relapse is an exclusion
- Concurrent use of systemic steroids at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well
- Active hepatitis B or active hepatitis C
- HIV Infection
- Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy
- CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity
- Uncontrolled active infection
- Pregnant or nursing (lactating) women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 29 years old?
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Amanda DiNofia, MDTaking people
About the trial
What the trial wants to find out
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT) (Cohort D).
The 4 groups in the trial
- Subjects with hypodiploid B-ALLTreatment being tested
Treatment: Murine CART19
- Subjects with t(17;19) B-ALLTreatment being tested
Treatment: Murine CART19
- Infant subjects with very high risk KMT2A B-ALLTreatment being tested
Treatment: Murine CART19
- Subjects with central nervous system (CNS) relapseTreatment being tested
who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT)
Treatment: Murine CART19
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)
- Plain-language title
- Tests CAR T cell therapy in children with hard-to-treat B cell leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04276870, who can take part
- Record updated
- 6 March 2026